Should I buy or sell Orchestra BioMed stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OBIO shares. View OBIO analyst ratings or view top-rated stocks .

What is Orchestra BioMed's stock price target for 2024?

2 analysts have issued 12 month target prices for Orchestra BioMed's stock. Their OBIO share price targets range from $14.00 to $20.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 260.9% from the stock's current price. View analysts price targets for OBIO or view top-rated stocks among Wall Street analysts .

How have OBIO shares performed in 2024?

Orchestra BioMed's stock was trading at $9.13 at the beginning of the year. Since then, OBIO shares have decreased by 48.4% and is now trading at $4.71. View the best growth stocks for 2024 here .

When is Orchestra BioMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our OBIO earnings forecast .

How were Orchestra BioMed's earnings last quarter?

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.01. The company earned $0.26 million during the quarter, compared to analyst estimates of $1 million. Orchestra BioMed had a negative net margin of 1,779.71% and a negative trailing twelve-month return on equity of 58.32%.

How do I buy shares of Orchestra BioMed?

Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OBIO

Orchestra BioMed (OBIO) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free OBIO Stock Alerts

$4.71

+0.09 (+1.95%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.54
▼
$4.78
50-Day Range: $4.62
▼
$7.17
52-Week Range: $4.26
▼
$20.69

Volume: 30,255 shs
Average Volume: 37,278 shs
Market Capitalization: $168.52 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Get Orchestra BioMed alerts:

Orchestra BioMed MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 260.9% Upside
$17.00 Price Target
Short Interest: Bearish
4.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.66) to ($1.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.67 out of 5 stars

Medical Sector

851st out of 918 stocks

Surgical & Medical Instruments Industry

89th out of 97 stocks

3.5

Analyst's Opinion

Consensus Rating
Orchestra BioMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Orchestra BioMed has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.07% of the float of Orchestra BioMed has been sold short.
Short Interest Ratio / Days to Cover
Orchestra BioMed has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Orchestra BioMed has recently decreased by 2.10%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Orchestra BioMed does not currently pay a dividend.
Dividend Growth
Orchestra BioMed does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OBIO.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Orchestra BioMed this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for OBIO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orchestra BioMed insiders have not sold or bought any company stock.
Percentage Held by Institutions
53.55% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Orchestra BioMed are expected to decrease in the coming year, from ($1.66) to ($1.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Orchestra BioMed is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Orchestra BioMed is -3.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Orchestra BioMed has a P/B Ratio of 2.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad TradingTips

3 Sub-$10 Stocks to Buy for 2024

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

Get your FREE look at these THREE companies right here.

About Orchestra BioMed Stock (NASDAQ:OBIO)

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

OBIO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OBIO Stock News Headlines

April 15, 2024 | americanbankingnews.com

Comparing Orchestra BioMed (OBIO) and Its Peers

March 31, 2024 | msn.com

Orchestra BioMed: Continuing the Momentum into a Promising Future

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

March 31, 2024 | msn.com

Orchestra BioMed Bolsters Board with Healthcare Industry Veteran David Pacitti

March 29, 2024 | finance.yahoo.com

Orchestra BioMed Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

March 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Data

March 27, 2024 | investorplace.com

OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023

March 27, 2024 | globenewswire.com

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

April 19, 2024 | The Bull Report (Ad)

Healthcare Takes A Big Step Forward With The Help Of AI

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

March 26, 2024 | globenewswire.com

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

March 11, 2024 | msn.com

Orchestra BioMed's AVIM Therapy Demonstrates Promising Results in Controlling Hypertension

March 7, 2024 | globenewswire.com

Orchestra BioMed to Participate in Upcoming Investor Conferences

March 6, 2024 | globenewswire.com

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

February 16, 2024 | finance.yahoo.com

Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season

January 19, 2024 | benzinga.com

Orchestra BioMed Hldgs Stock (NASDAQ:OBIO), Short Interest Report

January 19, 2024 | msn.com

Jefferies starts Orchestra BioMed at buy, cites lead program opportunities

January 16, 2024 | morningstar.com

Orchestra BioMed Holdings Inc OBIO

January 8, 2024 | sg.finance.yahoo.com

Silicon Box Accelerates Industry Leadership With Production Commencement at its World Leading Advanced Packaging Facility and Series B Fundraising

January 3, 2024 | finance.yahoo.com

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has caught the attention of hedge funds investors who hold a sizeable 28% stake

December 18, 2023 | msn.com

BATL, SNCR and BVN are among pre market gainers

November 16, 2023 | finanznachrichten.de

Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

November 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO) and Bicycle Therapeutics (BCYC)

November 14, 2023 | uk.finance.yahoo.com

Orchestra BioMed Holdings, Inc. (OBIO)

November 13, 2023 | finance.yahoo.com

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

November 9, 2023 | finance.yahoo.com

Orchestra BioMed to Present at Upcoming Investor Conferences

November 7, 2023 | msn.com

AxoGen Non-GAAP EPS of $0.01 beats by $0.07, revenue of $41.3M beats by $1.03M

October 25, 2023 | finanznachrichten.de

OBiO Technology (Shanghai) Corp., Ltd.: OBiO Announces Strategic Partnership with Refreshgene to Realize Commercialization of Gene Therapy Product

See More Headlines

Receive OBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:OBIO
CUSIP: N/A
CIK: 1814114
Web: orchestrabiomed.com
Phone: 646-597-6980
Fax: N/A
Employees: 56
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $20.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +260.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-49,120,000.00
Net Margins: -1,779.71%
Pretax Margin: -1,779.71%
Return on Equity: -58.32%
Return on Assets: -41.47%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.95
Quick Ratio: 7.94

Sales & Book Value

Annual Sales: $2.76 million
Price / Sales: 61.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.90 per share
Price / Book: 2.48

Miscellaneous

Outstanding Shares: 35,780,000
Free Float: N/A
Market Cap: $168.52 million
Optionable: Not Optionable
Beta: 0.15

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. David P. Hochman (Age 49)
Founder, Chairman of the Board of Directors & CEO
Comp: $942k
Mr. Darren R. Sherman (Age 53)
Founder, President, COO & Director
Comp: $787k
Mr. Andrew Lawrence Taylor M.B.A. (Age 53)
Chief Financial Officer
Comp: $326.37k
Mr. William Reed Little (Age 52)
Executive VP of Corporate Development & Strategy
Dr. Yuval Hay Mika D.Sc (Age 65)
Ph.D., GM & CTO of Bioelectronic Therapies
Dr. George Papandreou Ph.D. (Age 59)
GM & Senior VP of Focal Therapies
Dr. Hans-Peter Stoll M.D.
Ph.D., Chief Clinical Officer
Dr. Avraham Matityahu Fischer M.D. (Age 68)
Senior Vice President of Medical Affairs & Innovation
Mr. Bob Laughner
Senior Vice President of Regulatory & Quality
Mr. Juan Lorenzo
Senior Vice President of Product Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

OBIO Stock Analysis - Frequently Asked Questions

Should I buy or sell Orchestra BioMed stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchestra BioMed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OBIO shares.
View OBIO analyst ratings or view top-rated stocks.
What is Orchestra BioMed's stock price target for 2024?: 2 analysts have issued 12 month target prices for Orchestra BioMed's stock. Their OBIO share price targets range from $14.00 to $20.00. On average, they anticipate the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 260.9% from the stock's current price.
View analysts price targets for OBIO or view top-rated stocks among Wall Street analysts.
How have OBIO shares performed in 2024?: Orchestra BioMed's stock was trading at $9.13 at the beginning of the year. Since then, OBIO shares have decreased by 48.4% and is now trading at $4.71.
View the best growth stocks for 2024 here.
When is Orchestra BioMed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our OBIO earnings forecast.

How were Orchestra BioMed's earnings last quarter?: Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) announced its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.01. The company earned $0.26 million during the quarter, compared to analyst estimates of $1 million. Orchestra BioMed had a negative net margin of 1,779.71% and a negative trailing twelve-month return on equity of 58.32%.
How do I buy shares of Orchestra BioMed?: Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OBIO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial